Advancing Tumor Vaccines: Overcoming TME Challenges, Delivery Strategies, and Biomaterial-based Vaccine for Enhanced Immunotherapy

Qingsong Zeng; Shibo Zhang; Ning Leng; Yingying Xing

doi:10.1016/j.critrevonc.2024.104576

Advancing Tumor Vaccines: Overcoming TME Challenges, Delivery Strategies, and Biomaterial-based Vaccine for Enhanced Immunotherapy

Crit Rev Oncol Hematol. 2024 Nov 22:104576. doi: 10.1016/j.critrevonc.2024.104576. Online ahead of print.

Authors

Qingsong Zeng¹, Shibo Zhang¹, Ning Leng¹, Yingying Xing²

Affiliations

¹ School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People'sRepublic of China.
² School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, People'sRepublic of China. Electronic address: cpuskyxyy@126.com.

PMID: 39581246
DOI: 10.1016/j.critrevonc.2024.104576

Abstract

Tumor vaccines, as an immunotherapeutic approach, harness the body's immune cells to provoke antitumor responses, which have shown promising efficacy in clinical settings. However, the immunosuppressive tumor microenvironment (TME) and the ineffective vaccine delivery systems hinder the progression of many vaccines beyond phase II trials. This article begins with a comprehensive review of the complex interactions between tumor vaccines and TME, summarizing the current state of vaccine clinical research. Subsequently, we review recent advancements in targeted vaccine delivery systems and explore biomaterial-based tumor vaccines as a strategy to improve the efficacy of both delivery systems and treatment. Finally, we have presented our perspectives on tumor vaccine development, aiming to advance the field towards the creation of more effective tumor vaccines.

Keywords: Biomaterial-Based Vaccine; Tumor Microenvironment; Tumor Vaccines; Vaccine Delivery Systems.

Publication types

Review